Published 30 April 2026
Summary
Aegon Funding Co LLC (gtd. Aegon Ltd) launched a $500m WNG 10Y senior unsecured at IPT T+155 area, settling 7 May 2036. Ratings Baa1/BBB+. Use of proceeds funds a concurrent Reg S-only tender for legacy subordinated notes from non-US holders, with residual to general corporate purposes. Our fair value triangulates to T+125-130, implying ~25-30bp of starting concession at IPT and a likely landing of T+125-130 with NIC printing flat to slightly through.
Deal Terms
| Issuer | AEGON Funding Co LLC (gtd. Aegon Ltd) |
|---|
| Format | SEC-registered, senior unsecured |
|---|
| Size | $500m WNG |
|---|
| Tenor | 10Y bullet (7 May 2036) |
|---|
| IPT | T+155 area |
|---|
| Ratings | Baa1 / BBB+ |
|---|
| Calls | 3M par call, MWC, tax call |
|---|
| UoP | Tender for legacy subs (non-US holders) + GCP |
|---|
| Settlement | 7 May 2026 (T+5) |
|---|
How We Got to Fair Value
European multi-line life holdco senior is the right cohort, not US BBB+ life/annuity spread businesses (Athene, Brighthouse). Cross-currency translation from EUR/GBP curves to USD adds ~30-40bp Yankee premium for this issuer set.
| Comp |
Rating |
10Y EUR Z-spd |
Implied USD 10Y |
| Allianz | Aa3 / AA | +45-55 | T+75-90 |
| AXA SA | A2 / A | +62-66 | T+95-110 |
| NN Group | Baa1 / A- | +40-55 | T+85-105 |
| Aegon (FV) | Baa1 / BBB+ | — | T+115-138 |
Aegon's own USD curve confirms: Aegon Funding 5.50% Apr-2027 trades T+81 at 1Y. Applying the European multi-line 1s10s slope (~5-7bp/year in the belly) extrapolates to T+125-140 at 10Y, consistent with the cross-currency triangulation.
NIC at IPT vs Likely Landing
| Metric |
Value |
| FV central case | T+128 |
| FV range | T+115-138 |
| IPT | T+155 |
| Starting concession | ~25-30bp |
| Expected landing | T+125-130 |
| NIC at print | -3 to flat |
| Expected final size | $500m WNG (no upsize) |
| All-in yield (at landing) | ~5.65-5.70% |
Observations
- WNG sizing and 5-bank syndicate (BofA / Citi / DB / MS / WFC) support a tight clear.
- The sub tender is mildly negative for senior cushion — worth confirming whether concurrent or recent T2/RT1 supply offsets the equity-credit reduction.
- Tender targets are likely the Dutch-ISIN USD CMS perp and EUR perps trading in the high-70s to low-80s cash.
- BBB+ European multi-line cohort sits inside US BBB+ life/annuity peers; mis-anchoring on Athene would overstate FV by 15-25bp.
Disclaimer: This post is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Fair value estimates are observations based on publicly available curve data and may differ materially from actual market levels. Spreads, yields, and pricing are subject to change without notice. Readers should conduct their own analysis and consult appropriate professional advisors before making any investment decision. The author may or may not hold positions in the securities discussed. No representation or warranty is made as to the accuracy or completeness of the information provided.
